Integrating Circulating Tumor DNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer

DNA was isolated from pre-treatment and mid-treatment plasma samples and matched germline samples from patients undergoing chemoradiation therapy for stage IIB-IIIB non-small cell lung cancer. Sequencing libraries were hybrid captured using custom selector pools designed to target genes frequently mutated in non-small cell lung cancer prior to ultra-deep next generation sequencing.]]>
Inclusion:Patients with American Joint Committee on Cancer (AJCC) 7th edition stage IIB-IIIB non-small cell lung cancerTreated with definitive chemoradiation with concurrent platinum doublet chemotherapy at MD Anderson Cancer Center Pre-treatment and mid-treatment plasma samples collected for circulating tumor DNA analysisExclusion:No tumor variants identified in pre-treatment plasma sampleCirculating tumor DNA response during consolidation anti-PD-L1 immunotherapy]]>